55 related articles for article (PubMed ID: 29678527)
1. Improving Tumor Hypoxia Location in
Gertsenshteyn I; Epel B; Barth E; Leoni L; Markiewicz E; Tsai HM; Fan X; Giurcanu M; Bodero D; Zamora M; Sundramoorthy S; Kim H; Freifelder R; Bhuiyan M; Kucharski A; Karczmar G; Kao CM; Halpern H; Chen CT
Radiol Imaging Cancer; 2021 Mar; 3(2):e200104. PubMed ID: 33817651
[TBL] [Abstract][Full Text] [Related]
2. Effect of Time-of-Flight and Regularized Reconstructions on Quantitative Measurements and Qualitative Assessments in Newly Diagnosed Prostate Cancer With
Behr SC; Mollard BJ; Yang J; Flavell RR; Hawkins RA; Seo Y
Mol Imaging; 2017; 16():1536012117736703. PubMed ID: 29169313
[TBL] [Abstract][Full Text] [Related]
3. Prostate tumour visualisation with PET: is image fusion with MRI the answer?
Mehawed G; Murray R; Rukin NJ; Roberts MJ
BJU Int; 2024 Apr; 133 Suppl 4():4-6. PubMed ID: 38477216
[No Abstract] [Full Text] [Related]
4. Development of a PET/EPRI combined imaging system for assessing tumor hypoxia.
Kim H; Epel B; Sundramoorthy S; Tsai HM; Barth E; Gertsenshteyn I; Halpern H; Hua Y; Xie Q; Chen CT; Kao CM
J Instrum; 2021 Mar; 16(3):. PubMed ID: 33868448
[TBL] [Abstract][Full Text] [Related]
5. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.
Klotz L; Shayegan B; Guillemette C; Collins LL; Gotto G; Guérette D; Jammal MP; Pickles T; Richard PO; Saad F
Can Urol Assoc J; 2018 Feb; 12(2):30-37. PubMed ID: 29680011
[TBL] [Abstract][Full Text] [Related]
6. Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer.
Cherrier MM; Cross DJ; Higano CS; Minoshima S
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):394-402. PubMed ID: 29700388
[TBL] [Abstract][Full Text] [Related]
7. A narrative review and update on management following negative prostate biopsy.
Cheung DC; Li J; Finelli A
Curr Opin Urol; 2018 Jul; 28(4):398-402. PubMed ID: 29702497
[TBL] [Abstract][Full Text] [Related]
8. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
[TBL] [Abstract][Full Text] [Related]
9. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
[TBL] [Abstract][Full Text] [Related]
10. Nomograms are key decision-making tools in prostate cancer radiation therapy.
Caulfield S; Menezes G; Marignol L; Poole C
Urol Oncol; 2018 Jun; 36(6):283-292. PubMed ID: 29680180
[TBL] [Abstract][Full Text] [Related]
11. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
[TBL] [Abstract][Full Text] [Related]
12. Uncovering the Secrets of Prostate Cancer's Radiotherapy Resistance: Advances in Mechanism Research.
Lyu F; Shang SY; Gao XS; Ma MW; Xie M; Ren XY; Liu MZ; Chen JY; Li SS; Huang L
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371723
[TBL] [Abstract][Full Text] [Related]
13. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
[TBL] [Abstract][Full Text] [Related]
15. Utility of
Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
[No Abstract] [Full Text] [Related]
16. Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer.
Tharmalingam H; Tsang YM; Alonzi R; Beasley W; Taylor NJ; McWilliam A; Padhani A; Choudhury A; Hoskin PJ
Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):e246-e253. PubMed ID: 35033410
[TBL] [Abstract][Full Text] [Related]
17. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.
Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Koike R; Nishikawa T; Ishikawa K; Tamura M; Hosono M
J Radiat Res; 2013 Nov; 54(6):1078-84. PubMed ID: 23589026
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
19.
Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
